These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 14530466)

  • 1. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.
    Bushnell D; O'Dorisio T; Menda Y; Carlisle T; Zehr P; Connolly M; Karwal M; Miller S; Parker S; Bouterfa H
    J Nucl Med; 2003 Oct; 44(10):1556-60. PubMed ID: 14530466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
    Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
    Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
    Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
    Otte A; Herrmann R; Mäcke HR; Müller-Brand J
    Praxis (Bern 1994); 1999 Aug; 88(31-32):1263-8. PubMed ID: 10479965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
    Waldherr C; Pless M; Maecke HR; Schumacher T; Crazzolara A; Nitzsche EU; Haldemann A; Mueller-Brand J
    J Nucl Med; 2002 May; 43(5):610-6. PubMed ID: 11994522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
    Waldherr C; Haldemann A; Maecke HR; Crazzolara A; Mueller-Brand J
    Clin Oncol (R Coll Radiol); 2000; 12(2):121-3. PubMed ID: 10853753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy.
    Virgolini I; Traub T; Leimer M; Novotny C; Pangerl T; Ofluoglu S; Halvadjieva E; Smith-Jones P; Flores J; Li SR; Angelberger P; Havlik E; Andreae F; Raderer M; Kurtaran A; Niederle B; Dudczak R
    Q J Nucl Med; 2000 Mar; 44(1):50-8. PubMed ID: 10932601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide receptor imaging and therapy.
    Kwekkeboom D; Krenning EP; de Jong M
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
    Savelli G; Bertagna F; Franco F; Dognini L; Bosio G; Migliorati E; Rodella C; Biasiotto G; Bettinsoli G; Minari C; Zaniboni A; Ferrari C; Tomassetti P; Ferrari V; Giubbini R
    Cancer; 2012 Jun; 118(11):2915-24. PubMed ID: 22020784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.
    McCarthy KE; Woltering EA; Espenan GD; Cronin M; Maloney TJ; Anthony LB
    Cancer J Sci Am; 1998; 4(2):94-102. PubMed ID: 9532411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
    Bushnell D; Menda Y; Madsen M; O'Dorisio T; Carlisle T; Zehr P; Ponto L; Karwal M; Parker S; Ponto J; Connolly M; Bouterfa H
    Cancer Biother Radiopharm; 2003 Aug; 18(4):581-8. PubMed ID: 14503953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
    Smith MC; Liu J; Chen T; Schran H; Yeh CM; Jamar F; Valkema R; Bakker W; Kvols L; Krenning E; Pauwels S
    Digestion; 2000; 62 Suppl 1():69-72. PubMed ID: 10940690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.
    Hindorf C; Chittenden S; Causer L; Lewington VJ; Mäcke HR; Flux GD
    Cancer Biother Radiopharm; 2007 Feb; 22(1):130-5. PubMed ID: 17627421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.
    Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; deHerder WW; vanEijck CH; Kwekkeboom DJ; deJong M; Pauwels S
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S219-23. PubMed ID: 10604135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.